What is the Anika Therapeutics Inc. stock price forecast?

Anika Therapeutics Inc. is currently trading at $14.30. View real-time AI analysis on Alpha Lenz.

What is Anika Therapeutics Inc. insider trading activity?

View the latest insider trading data for Anika Therapeutics Inc. on Alpha Lenz.

What is Anika Therapeutics Inc.'s P/E ratio?

Anika Therapeutics Inc.'s P/E ratio is -18.8.

Anika Therapeutics Inc.

NASDAQ · ANIK

$14.30-0.31(-2.12%)Pre-market

Ask about Anika Therapeutics Inc.'s future dividend policy...

Alpha Chat Insight

“Anika Therapeutics Inc. trades at a P/E of -18.8 (undervalued) with modest ROE of -7.3%.”

Ask for details →

Company Overview

Anika Therapeutics Inc. is a prominent player in the healthcare sector, specifically known for its focus on biotechnology and medical devices. The company is dedicated to developing, manufacturing, and commercializing therapeutic products for tissue protection, healing, and repair. It primarily targets musculoskeletal conditions, offering solutions for osteoarthritis pain management through viscosupplementation products. Anika Therapeutics also delves into regenerative medicine, providing products that aid in surgical repair and regenerative tissue growth. By addressing the needs of orthopedic care, Anika Therapeutics impacts both healthcare providers and patients, enhancing quality of life and promoting recovery. With its research and development facilities, the company continuously strives to innovate new treatments to support its mission of improving patient outcomes globally. Anika Therapeutics Inc. plays a crucial role in advancing global healthcare solutions, fostering collaborations and extending its impact across multiple medical disciplines.

CEODr. Cheryl Renee Blanchard Ph.D.

Websitehttps://www.anika.com

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Employees288

Company Statistics

FY 2025

Profile

$205.05MMarket Cap

$112.82MRevenue

0.00Shares Out

288Employees

Margins

56.56%Gross

-4.72%EBITDA

-9.80%Operating

-8.25%Pre-Tax

-9.64%Net

Valuation

-18.85P/E

1.43P/B

1.82EV/Sales

-32.66EV/EBITDA

47.01P/FCF

Growth (CAGR)

-10.28%Rev 3Yr

-2.86%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-5.54%ROA

-7.32%ROE

-5.62%ROIC

Financial Health

$57.48MCash & Cash Equivalents

$-10.68MNet Debt

32.62%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Anika Therapeutics Inc. trades at a P/E of -18.8 (undervalued) with modest ROE of -7.3%.”

Ask for details →

Frequently Asked Questions

Anika Therapeutics Inc. (ticker: ANIK) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 288 employees. Market cap is $205M.

The current price is $14.3 with a P/E ratio of -18.85x and P/B of 1.43x.

ROE is -7.32% and operating margin is -9.80%. Annual revenue is $113M.